EXHIBIT A
THE CLAIMS WHICH WILL BE PENDING
UPON ENTRY OF THE PRESENT AMENDMENT
U.S. PATENT APPLICATION NO. 09/992,107

55. A pharmaceutical composition for the treatment of a vascular disease or condition selected from the group consisting of atherosclerosis, hyperlipidemia, and hypoalphalipoproteinemia in a human, comprising a pharmaceutically acceptable and a therapeutically effective amount of unilamellar phospholipid liposomes free of drug wherein at least 68% of the liposomes have a mean diameter of about 125 ± 30 nm, which liposomes mobilize more cholesterol than an equal amount of unilamellar phospholipid liposomes having a mean diameter of 30 ± 7 nm as measured in mice.

56. The pharmaceutical composition of claim 55 wherein 68% of the liposomes have a mean diameter between about 100-150 nm.

57. The pharmaceutical composition of claim 55 in which the therapeutically effective amount is about 0.1-1.5 gm/kg.

58. The pharmaceutical composition of claim 55 in which the therapeutically effective amount is about 0.28-0.42 gm/kg.

59. The pharmaceutical composition of claim 55 in which the therapeutically effective amount is about 300 mg per kg body weight.

60. The pharmaceutical composition of claim 55 comprising a pharmaceutically acceptable carrier selected from the group consisting of sterilized water, sterilized buffered water, sterilized saline solution, and a sterilized aqueous solution.

61. The pharmaceutical composition of claim 60 wherein the pharmaceutically acceptable carrier contains a compound selected from the group consisting of glycine, a glycoprotein, albumin, a lipoprotein, a globulin, a pH adjusting agent, a buffering agent, a tonicity adjusting agent, sodium acetate, sodium lactate, sodium phosphate, potassium chloride, calcium chloride, sodium chloride, and mixtures thereof.

62. The pharmaceutical composition of claim 60 wherein the concentration of liposomes in the carrier is in the range of about 20-200 mg/ml.

63. The pharmaceutical composition of claim 60 wherein the concentration of liposomes in the carrier is about 200 mg/ml.

64. The pharmaceutical composition of claim 60 wherein the concentration of liposomes in the carrier is in the range of about 50-150 mg/ml.

65. The pharmaceutical composition of claim 60 wherein the concentration of liposomes in the carrier is about 100 mg/ml.

66. The pharmaceutical composition of claim 55 wherein the composition is lyophilized.

67. The pharmaceutical composition of claim 55, wherein the phospholipid is selected from the group consisting of egg phosphatidylcholine, egg phosphatidylglycerol, distearoylphosphatidylcholine, distearoylphosphatidylglycerol, phosphatidylcholine, phosphatidylglycerol, lecithin, β,γ-dipalmitoyl-α-lecithin, sphingomyelin, phosphatidylserine, phosphatidic acid, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylinositol, cephalin, cardiolipin, oleoyl-palmitoyl-phosphatidylcholine, dioleoylphosphatidylcholine, dipalmitoylphosphatidylcholine, dipalmitoylphosphatidylglycerol, dioleoylphosphatidylglycerol, palmitoyl-oleoyl-phosphatidylcholine, di-stearoyl-phosphatidylcholine, stearoyl-palmitoyl-phosphatidylcholine, di-palmitoyl-phosphatidylethanolamine, di-stearoyl-phosphatidylethanolamine, di-myrstoyl-phosphatidylserine, and mixtures thereof.

68. The pharmaceutical composition of claim 55, wherein the phospholipid is selected from the group consisting of phosphatidylcholine, phosphatidylglycerol, and mixtures thereof.

69. The pharmaceutical composition of claim 55, wherein the phospholipids are in a liquid crystalline phase at about 37^0C.

70. A pharmaceutical composition for the treatment of a vascular disease or condition selected from the group consisting of atherosclerosis, hyperlipidemia, and hypoalphalipoproteinemia in a human, comprising a pharmaceutically acceptable and a therapeutically effective amount of unilamellar phospholipid liposomes free of drug which liposomes are effective in promoting cholesterol efflux without causing a substantial increase in LDL or esterified cholesterol levels.

71. The pharmaceutical composition of claim 70 wherein the liposomes have a mean diameter between about 100-150 nm.

72. The pharmaceutical composition of claim 70 in which the therapeutically effective amount is about 0.1-1.5 gm/kg.

73. The pharmaceutical composition of claim 70 in which the therapeutically effective amount is about 0.28-0.42 gm/kg.

74. The pharmaceutical composition of claim 70 in which the therapeutically effective amount is about 300 mg per kg body weight.

75. The pharmaceutical composition of claim 70 comprising a pharmaceutically acceptable carrier selected from the group consisting of sterilized water, sterilized buffered water, sterilized saline solution, and a sterilized aqueous solution.

76. The pharmaceutical composition of claim 75 wherein the pharmaceutically acceptable carrier contains a compound selected from the group consisting of glycine, a glycoprotein, albumin, a lipoprotein, a globulin, a pH adjusting agent, a buffering agent, a tonicity adjusting agent, sodium acetate, sodium lactate, sodium phosphate, potassium chloride, calcium chloride, sodium chloride, and mixtures thereof.

77. The pharmaceutical composition of claim 75 wherein the concentration of liposomes in the carrier is in the range of about 20-200 mg/ml.

78. The pharmaceutical composition of claim 75 wherein the concentration of liposomes in the carrier is about 200 mg/ml.

79. The pharmaceutical composition of claim 75 wherein the concentration of liposomes in the carrier is in the range of about 50-150 mg/ml.

80. The pharmaceutical composition of claim 75 wherein the concentration of liposomes in the carrier is about 100 mg/ml.

81. The pharmaceutical composition of claim 70 wherein the composition is lyophilized.

82. The pharmaceutical composition of claim 70, wherein the phospholipid is selected from the group consisting of egg phosphatidylcholine, egg phosphatidylglycerol, distearoylphosphatidylcholine, distearoylphosphatidylglycerol, phosphatidylcholine, phosphatidylglycerol, lecithin, β,γ-dipalmitoyl-α-lecithin, sphingomyelin, phosphatidylserine, phosphatidic acid, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylinositol, cephalin, cardiolipin, oleoyl-palmitoyl-phosphatidylcholine, dipalmitoylphosphatidylcholine, dipalmitoylphosphatidylglycerol, dioleoylphosphatidylglycerol, palmitoyl-oleoyl-phosphatidylcholine, di-stearoyl-phosphatidylcholine, stearoyl-palmitoyl-phosphatidylcholine, di-palmitoyl-phosphatidylethanolamine, di-stearoyl-phosphatidylethanolamine, di-myrstoyl-phosphatidylserine, and mixtures thereof.

83. The pharmaceutical composition of claim 70, wherein the phospholipid is selected from the group consisting of phosphatidylcholine, phosphatidylglycerol, and mixtures thereof.

84. The pharmaceutical composition of claim 70, wherein the phospholipids are in a liquid crystalline phase at about 37^0C.